
    
      Healthy subjects will be enrolled and will receive 2, 6, and 12 inhalations from both the
      test and reference pMDI products according to a six-period cross-over design.
      Electrocardiograms (ECGs) and plasma potassium and glucose levels will be measured pre-dose
      and over 6 hours post-dose.
    
  